Biblio

Author Title Type [ Year

]

Filters: Author is Champlin, Richard E [Clear All Filters]

2019

Santos, D.M.Cordas D., Saliba, R.M., Patel, R., Bashir, Q., Saini, N., Hosing, C., Kebriaei, P., Khouri, I.F., Nieto, Y., Popat, U., et al. (2019). Age is a prognostic factor for the overall survival of multiple myeloma patients undergoing upfront autologous hematopoietic stem cell transplantation.Biol Blood Marrow Transplant.

Chamoun, K., Milton, D.R., Ledesma, C., Young, K.H., Jabbour, E.J., Alatrash, G., Anderlini, P., Bashir, Q., Ciurea, S.O., Marin, D., et al. (2019). Allogeneic Transplantation after Myeloablative Rituximab/BEAM +/- Bortezomib for Patients with Relapsed/Refractory Lymphoid Malignancies: 5-Year Follow-up Results.Biol Blood Marrow Transplant.

Ciurea, S.O., Hansrivijit, P., Ciurea, A.M., Hymes, S., Chen, J., Rondon, G., Hosing, C., Popat, U., and Champlin, R.E. (2019). Curative Potential of Hematopoietic Stem Cell Transplantation for Advanced Psoriasis.Am J Hematol.

Srour, S.A., Saliba, R.M., Bittencourt, M.Cb, Perez, J.Miguel Ram, Kongtim, P., Alousi, A., Al-Atrash, G., Olson, A., Betul, O., Mehta, R., et al. (2019). Haploidentical Transplantation for Acute Myeloid Leukemia Patients with Minimal/ Measurable Residual Disease at Transplantation.Am J Hematol.

Saini, N.Y., Saliba, R.M., Rondon, G., Maadani, F., Popat, U., Hosing, C.M., Betul, O., Bashir, Q., Olson, A., Nieto, Y., et al. (2019). Impact of Donor Type and Melphalan Dose on Allogeneic Transplant Outcomes for Patients with Lymphoma.Biol Blood Marrow Transplant.

Li, L., Chen, H., Marin, D., Xi, Y., Miao, Q., Lv, J., Banerjee, P.Prosad, Shaim, H., Daher, M., Basar, R., et al. (2019). A novel immature natural killer cell subpopulation predicts relapse after cord blood transplantation.Blood Adv3, 4117-4130.

Varma, A., Sui, D., Milton, D.R., Tang, G., Saini, N., Hasan, O., Mukherjee, A., Joseph, J.Joy, Bashir, Q., Rondon, G., et al. (2019). Outcome of Multiple Myeloma With Chromosome 1q Gain and 1p Deletion After Autologous Hematopoietic Stem Cell Transplantation: propensity-score matched analysis: Outcome of 1q+/1p- MM pts after auto-HCT.Biol Blood Marrow Transplant.

2018

de Lima, M., Oran, B., Champlin, R.E., Papadopoulos, E.B., Giralt, S.A., Scott, B.L., William, B.M., Hetzer, J., Laille, E., Hubbell, B., et al. (2018). CC-486 Maintenance After Stem Cell Transplantation in Patients with Acute Myeloid Leukemia or Myelodysplastic Syndromes.Biol Blood Marrow Transplant.

Valdez, B.C., Tang, X., Li, Y., Murray, D., Liu, Y., Popat, U., Champlin, R.E., and Andersson, B.S. (2018). Epigenetic modification enhances the cytotoxicity of busulfan and 4-hydroperoxycyclophosphamide in AML cells.Exp Hematol.

Afrough, A., Saliba, R.M., Hamdi, A., Honhar, M., Varma, A., A Cornelison, M., Rondon, G., Parmar, S., Shah, N.D., Bashir, Q., et al. (2018). Impact of Induction Therapy on the Outcome of Immunoglobulin Light Chain Amyloidosis after Autologous Hematopoietic Stem Cell Transplantation.Biol Blood Marrow Transplant.

Saini, N.Y., Patel, R., Varma, A., Bashir, Q., Delgado, R., Rondon, G., Popat, U.R., Hosing, C.M., Nieto, Y., Kebriaei, P., et al. (2018). Melphalan based autologous transplant in octogenarian multiple myeloma patients.Am J Hematol.

Edwards, B.J., Zhang, X., Sun, M., Song, J., Khalil, P., Karuturi, M.Sri, Pang, L., Geng, Y., Dinney, C.P., Valero, V., et al. (2018). Overall survival in older patients with cancer.Bmj Support Palliat Care.

Sheshadri, A., Chemaly, R.F., Alousi, A.M., Shah, P.K., Rondon, G., Bashoura, L., Kmeid, J., Azzi, J., Blanco, D.W., Kaous, M., et al. (2018). Pulmonary impairment following respiratory viral infections is associated with high mortality in allogeneic hematopoietic cell transplant recipients.Biol Blood Marrow Transplant.

2016

Valdez, B.C., Li, Y., Murray, D., Brammer, J.E., Liu, Y., Hosing, C., Nieto, Y., Champlin, R.E., and Andersson, B.S. (2016). Differential effects of histone deacetylase inhibitors on cellular drug transporters and their implications for using epigenetic modifiers in combination chemotherapy.Oncotarget.

Jabbour, E., Short, N.J., Jorgensen, J.L., Yilmaz, M., Ravandi, F., Wang, S.A., Thomas, D.A., Khoury, J., Champlin, R.E., Khouri, I., et al. (2016). Differential impact of minimal residual disease negativity according to the salvage status in patients with relapsed/refractory B-cell acute lymphoblastic leukemia.Cancer.

Kebriaei, P., Singh, H., M Huls, H., Figliola, M.J., Bassett, R., Olivares, S., Jena, B., Dawson, M.J., Kumaresan, P.R., Su, S., et al. (2016). Phase I trials using Sleeping Beauty to generate CD19-specific CAR T cells.J Clin Invest.

Short, N.J., Kantarjian, H.M., Sasaki, K., Cortes, J.E., Ravandi, F., Thomas, D.A., Garcia-Manero, G., Khouri, I., Kebriaei, P., Champlin, R.E., et al. (2016). Prognostic significance of day 14 bone marrow evaluation in adults with Philadelphia chromosome-negative acute lymphoblastic leukemia.Cancer.

Aung, F.M., Lichtiger, B., Rondon, G., C Yin, C., Alousi, A., Ahmed, S., Andersson, B., Bashier, Q., Ciurea, S.O., Hosing, C., et al. (2016). Pure Red Cell Aplasia in Major ABO Mismatched Allogeneic Hematopoietic Stem Cell Transplantation is Associated with Severe Pancytopenia.Biol Blood Marrow Transplant.

Thokala, R., Olivares, S., Mi, T., Maiti, S., Deniger, D., Huls, H., Torikai, H., Singh, H., Champlin, R.E., Laskowski, T., et al. (2016). Redirecting Specificity of T cells Using the Sleeping Beauty System to Express Chimeric Antigen Receptors by Mix-and-Matching of VL and VH Domains Targeting CD123+ Tumors.Plos One11, e0159477.

Gaballa, S., Ge, I., Fakih, R.El, Brammer, J.E., Kongtim, P., Tomuleasa, C., Wang, S.A., Lee, D., Petropoulos, D., Cao, K., et al. (2016). Results of a 2-arm, phase 2 clinical trial using post-transplantation cyclophosphamide for the prevention of graft-versus-host disease in haploidentical donor and mismatched unrelated donor hematopoietic stem cell transplantation.Cancer.

Valdez, B.C., Brammer, J.E., Li, Y., Murray, D., Teo, E.C., Liu, Y., Hosing, C., Nieto, Y., Champlin, R.E., and Andersson, B.S. (2016). Romidepsin enhances the cytotoxicity of fludarabine, clofarabine and busulfan combination in malignant T-cells.Leuk Res47, 100-108.

Brammer, J.E., Khouri, I., Marin, D., Ledesma, C., Rondon, G., Ciurea, S.O., Nieto, Y., Champlin, R.E., Hosing, C., and Kebriaei, P. (2016). Stem cell transplantation outcomes in lymphoblastic lymphoma.Leuk Lymphoma1-6.

2015

Oran, B., Jimenez, A.M., de Lima, M., Popat, U.R., Bassett, R., Andersson, B., Borthakur, G., Bashir, Q., Chen, J., Ciurea, S.O., et al. (2015). Age and Modified European LeukemiaNet Classification to Predict Transplant Outcomes: An Integrated Approach for Acute Myelogenous Leukemia Patients Undergoing Allogeneic Stem Cell Transplantation.Biol Blood Marrow Transplant.

Kongtim, P., Lee, D.A., Cooper, L.J.N., Kebriaei, P., Champlin, R.E., and Ciurea, S.O. (2015). Haploidentical Hematopoietic Stem Cell Transplantation as Platform for Post-transplant Cellular Therapy.Biol Blood Marrow Transplant.

Ravandi, F., Jorgensen, J.L., O'Brien, S.M., Jabbour, E., Thomas, D.A., Borthakur, G., Garris, R., Huang, X., Garcia-Manero, G., Burger, J.A., et al. (2015). Minimal residual disease assessed by multi-parameter flow cytometry is highly prognostic in adult patients with acute lymphoblastic leukaemia.Br J Haematol.

Pages